P05.06 Phase 2 study to evaluate the safety, pharmacokinetics and clinical activity of PI3K/mTOR inhibitor GDC-0084 given to glioblastoma (GBM) patients with unmethylated O(6)-methylguanine-methyltransferase (MGMT) promoter status

BACKGROUND: GDC-0084 is a potent, oral, selective small molecule inhibitor of class I phosphoinositide 3-kinase and mammalian target of rapamycin (PI3K/mTOR). The PI3K pathway is activated in ≥ 70% of tumors, making it a compelling target for the treatment of GBM. GDC-0084 crosses the blood-brain ba...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Wen, P Y, de Groot, J, Battiste, J D, Goldlust, S A, Garner, J, Simpson, J, Olivero, A, Cloughesy, T
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Poster Presentations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6796036/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.120
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items